[go: up one dir, main page]

DK1680430T3 - Fremgangsmåder til fremstilling af form I af (S)-(+)-Clopidogrel-bisulfat - Google Patents

Fremgangsmåder til fremstilling af form I af (S)-(+)-Clopidogrel-bisulfat

Info

Publication number
DK1680430T3
DK1680430T3 DK04820865.6T DK04820865T DK1680430T3 DK 1680430 T3 DK1680430 T3 DK 1680430T3 DK 04820865 T DK04820865 T DK 04820865T DK 1680430 T3 DK1680430 T3 DK 1680430T3
Authority
DK
Denmark
Prior art keywords
clopidogrel bisulfate
methods
preparing form
preparation
clopidogrel
Prior art date
Application number
DK04820865.6T
Other languages
English (en)
Inventor
Braj Lohray
Vidya Lohray
Bipin Pandey
Mayank Ghanshyambhai Dave
Parind Narendra Dholakia
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Application granted granted Critical
Publication of DK1680430T3 publication Critical patent/DK1680430T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
DK04820865.6T 2003-11-03 2004-11-02 Fremgangsmåder til fremstilling af form I af (S)-(+)-Clopidogrel-bisulfat DK1680430T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1154MU2003 2003-11-03
IN1217MU2003 2003-11-25
PCT/IN2004/000341 WO2005063708A2 (en) 2003-11-03 2004-11-02 Processes for preparing different forms of (s)-(+)- clopidogrel bisulfate

Publications (1)

Publication Number Publication Date
DK1680430T3 true DK1680430T3 (da) 2010-05-25

Family

ID=34740781

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04820865.6T DK1680430T3 (da) 2003-11-03 2004-11-02 Fremgangsmåder til fremstilling af form I af (S)-(+)-Clopidogrel-bisulfat

Country Status (12)

Country Link
US (2) US8907090B2 (da)
EP (2) EP2103617A1 (da)
KR (2) KR101050105B1 (da)
AT (1) ATE455778T1 (da)
CA (2) CA2544443C (da)
DE (1) DE602004025267D1 (da)
DK (1) DK1680430T3 (da)
ES (1) ES2339944T3 (da)
NO (1) NO20062062L (da)
PL (1) PL1680430T3 (da)
PT (1) PT1680430E (da)
WO (1) WO2005063708A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003238664A1 (en) * 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
PL1618111T3 (pl) * 2003-04-25 2015-06-30 Cadila Healthcare Ltd Sole klopidogrelu i sposób wytwarzania
EP2103617A1 (en) * 2003-11-03 2009-09-23 Cadila Healthcare Limited Processes for preparing different forms of (S)-(+)-clopidogrel bisulfate
WO2006074066A1 (en) * 2004-12-30 2006-07-13 Nektar Therapeutics Non-crystalline formulation comprising clopidogrel
KR20070066518A (ko) * 2005-12-22 2007-06-27 에스케이케미칼주식회사 고체상 반응을 이용한 (ｓ)-(＋)-클로피도그렐의 제조방법
KR101235117B1 (ko) 2005-12-26 2013-02-20 에스케이케미칼주식회사 광학분리에 의한 (ｓ)-(＋)-클로피도그렐의 제조방법
US20090093635A1 (en) * 2006-03-09 2009-04-09 Sandor Garadnay PROCESS FOR MAKING POLYMORPH FROM I OF (S) - (+) -METHYL-ALPHA- (2-CHLOROPHENYL) -6, 7-DYHIDRO-THIENO- [3, 2-c] PYRIDINE-5 (4H) -ACETATE HYDROGEN SULFATE
KR101378596B1 (ko) * 2006-12-27 2014-03-26 경동제약 주식회사 결정성 클로피도그렐 · 황산염 형태 ｉ의 제조방법
EP2107061A1 (en) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
BRPI0914238A2 (pt) * 2008-06-24 2015-08-04 Zach System Spa Processo para a preparação da forma cristalina i de hidrogenossulfato de clopidogrel.
KR101616928B1 (ko) * 2010-01-07 2016-05-02 동화약품주식회사 클로피도그렐 황산수소염 결정형（ｉ）의 제조방법
CN102558194A (zh) * 2010-12-11 2012-07-11 山东方明药业股份有限公司 一种硫酸氢氯吡格雷i型的制备方法
KR101567438B1 (ko) 2013-11-15 2015-11-12 대구가톨릭대학교산학협력단 클로피도그렐 황산염 결정형 ⅰ형의 제조방법
KR101710922B1 (ko) 2015-06-03 2017-02-28 경동제약 주식회사 클로피도그렐 황산염 결정형 i형의 제조방법
CN107163060B (zh) * 2017-05-24 2021-03-02 常州制药厂有限公司 一种硫酸氢氯吡格雷晶型ii制备方法
CN113121559B (zh) * 2019-12-31 2023-08-29 惠州信立泰药业有限公司 一种高堆密度的ii型硫酸氢氯吡格雷球形结晶及制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2652575B1 (fr) 1989-09-29 1992-01-24 Sanofi Sa Procede de preparation d'acides alpha-bromo phenylacetiques.
FR2664276B1 (fr) 1990-07-04 1992-10-23 Sanofi Sa Derive thienyl-2 glycidique, son procede de preparation et son utilisation comme intermediaire de synthese.
FR2664596B1 (fr) 1990-07-10 1994-06-10 Sanofi Sa Procede de preparation d'un derive n-phenylacetique de tetrahydrothieno [3,2-c] pyridine et son intermediaire de synthese.
US5139170A (en) 1990-09-06 1992-08-18 Ad-Tech Plastic Systems Corp. Dispensing apparatus for multiple fluids
FR2760456B1 (fr) 1997-03-05 2000-05-12 Sanofi Sa Procede de preparation de derives de 2-thienyl-ethylamine
HU222283B1 (hu) 1997-05-13 2003-05-28 Sanofi-Synthelabo Eljárás tieno[3,2-c]piridin-származékok előállítására
HU225504B1 (en) 1997-05-13 2007-01-29 Sanofi Aventis Novel halophenyl-(2-(2-thienyl)-ethylamino)-acetonitriles and process for producing them
HU225503B1 (en) 1997-05-13 2007-01-29 Sanofi Aventis Novel 2-(2-halophenyl)-2-(2-(2-thienyl)-ethylamino)-acetamides and process for producing them
FR2769313B1 (fr) 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
IN191030B (da) 2001-01-24 2003-09-13 Cadila Healthcare Ltd
EA006198B2 (ru) 2001-01-24 2007-10-26 Кадила Хелзкэр Лтд. Способ получения клопидогрела
US6767913B2 (en) * 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
WO2003051362A2 (en) 2001-12-18 2003-06-26 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate
US7074928B2 (en) * 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
US6800759B2 (en) * 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
CZ297472B6 (cs) * 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
AU2003238664A1 (en) 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
PL1618111T3 (pl) * 2003-04-25 2015-06-30 Cadila Healthcare Ltd Sole klopidogrelu i sposób wytwarzania
JP2007516934A (ja) * 2003-08-04 2007-06-28 ウォックハート・リミテッド （＋）−（ｓ）−クロピドグレル重硫酸塩形態−ｉの新規な製造方法
EP2103617A1 (en) 2003-11-03 2009-09-23 Cadila Healthcare Limited Processes for preparing different forms of (S)-(+)-clopidogrel bisulfate
BRPI0418726A (pt) * 2004-04-09 2007-09-11 Hanmi Pharm Ind Co Ltd naftalenossulfonato de clopidogrel cristalino ou hidrato do mesmo, método para sua preparação e composição farmacêutica contendo o mesmo
US20060154957A1 (en) * 2004-09-21 2006-07-13 Nina Finkelstein Crystalline clopidogrel hydrobromide and processes for preparation thereof
US7446200B2 (en) * 2004-10-04 2008-11-04 Usv, Ltd. Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I

Also Published As

Publication number Publication date
KR101050105B1 (ko) 2011-07-19
KR20110010809A (ko) 2011-02-07
US20070082924A1 (en) 2007-04-12
ATE455778T1 (de) 2010-02-15
PT1680430E (pt) 2010-04-26
DE602004025267D1 (de) 2010-03-11
EP2103617A1 (en) 2009-09-23
CA2676121A1 (en) 2005-07-14
CA2544443A1 (en) 2005-07-14
PL1680430T3 (pl) 2010-06-30
US8907090B2 (en) 2014-12-09
US20100204268A1 (en) 2010-08-12
NO20062062L (no) 2006-07-24
KR20070006679A (ko) 2007-01-11
WO2005063708A3 (en) 2005-10-06
CA2544443C (en) 2010-08-17
EP1680430A2 (en) 2006-07-19
EP1680430B1 (en) 2010-01-20
ES2339944T3 (es) 2010-05-27
KR101110738B1 (ko) 2012-02-17
WO2005063708A2 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
NO20062062L (no) Procsesser for preparering av forskjellige former for (S)-(+)-clopidogrel bisulfat
ATE448303T1 (de) Vektoren zur gerichteten klonierung
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
DK1252824T3 (da) Fremgangsmåde til forbedring af knoglemineralisering
DE60325188D1 (de) Verfahren zur herstellung von sterilen, stabilisierten nanodispersionen
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK2058243T4 (da) Fremgangsmåde til fremstilling af drikke
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
BRPI0401163B1 (pt) composição de concentrado de aditivos auxiliadora de processo
ATE453648T1 (de) Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
DK1536685T3 (da) Fremgangsmåde til fremstilling af pasta-ekstruderede sulfonamidsammensætninger
DK1353923T3 (da) Forbedret fremgangsmåde til syntese af carbapenem
ATE461182T1 (de) Kristallines mycophenolat-natrium
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1656365T3 (da) Fremgangsmåde til fremstilling af enantiomerisk rent mirtazapin
DK1395587T3 (da) Fremgangsmåde til fremstilling af imipenem
NO20034584D0 (no) Fremgangsmåte for sulfidkonsentrasjon
DK1503995T3 (da) Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer
DK1401846T3 (da) Fremgangsmåde til udvinding af N-phosphonomethylglycin
DK1373232T3 (da) Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
DE602004030231D1 (de) Pyrimidinonverbindungen als calcilytica
DK1685104T3 (da) Fremgangsmåde til fremstilling af N-substituerede phthalomider
DK1632567T3 (da) Fremgangsmåde til fremstilling af phosphorylase